Psoriasis, a chronic inflammatory disease of the immune system that primarily affects skin and joints, affects nearly 7.5 million people in the United States.
According to the American Academy of Dermatology, the cost of psoriasis-associated treatment "was estimated to be between $51.7 billion and $63.2 billion," in 2013.
Marking Psoriasis Awareness Month, Healio Internal Medicine presents the 10 most popular stories on psoriasis thus far in 2016.
Psoriasis associated with type 2 diabetes, obesity in twin study
Psoriasis had a strong association with type 2 diabetes and obesity in a nationwide study of Danish twins, indicating a common genetic etiology between psoriasis and obesity, according to study results recently published in JAMA Dermatology. Read more.
show efficacy in year-long treatment of psoriasis
Research from two separate studies showing year-long efficacy results of for Taltz and Cosentyx treatments for psoriasis were presented at a late-breaking research forum at the American Academy of Dermatology Annual Meeting. Read more.
No significant difference found between
, methotrexate in treating psoriasis
There were no statistically significant differences found in efficacy between Otezla and methotrexate for moderate-to-severe psoriasis, according to recently published study results. Read more.
Patients with psoriasis treated with
reported improvements in work productivity
Patients with moderate-to-severe psoriasis who were treated with Taltz reported improvement in work productivity between 12 and 60 weeks compared with patients treated with placebo and, in some incidences, those treated with Enbrel, according to study results. Read more.
Psoriasis patients treated by lasers show no indication of
Patients with plaque psoriasis who underwent laser treatment did not show evidence of subsequent koebnerization, according to recent research. Read more.
effective in patients with palmoplantar psoriasis
Patients in this study with moderate-to-severe palmoplantar psoriasis showed clinical improvement at 16 weeks after treatment with Otezla compared with placebo, according to recent data. Read more.
Patients with psoriasis effectively switch from
to infliximab biosimilar
Patients with psoriasis being treated with Remicade had no significant change in clinical response and experienced minor adverse events when switching to an infliximab biosimilar, according to recently published study results. Read more.
shows continued efficacy for 60-week treatment of psoriasis
In a video perspective from the American Academy of Dermatology Annual Meeting, Andrew Blauvelt, MD, MBA, discusses his research showing that Taltz had continued efficacy in treating patients with psoriasis through week 60. Watch here.
superior to TNF-α inhibitors in treating psoriasis at 6, 12 months
Stelara was significantly more effective in treating patients with psoriasis compared with three tumor necrosis factor-alpha inhibitors at 6 months and 12 months, according to recently published study results. Read more.
Complete skin clearance represents meaningful endpoint for patients with psoriasis
Complete skin clearance in patients with psoriasis was a clinically meaningful endpoint and outcome, with no impairment on health-related quality of life, according to recently published study results. Read more.